Chromosomal microarray better informs brain tumor diagnosis
Answers from the Lab
Molecular biomarkers are a critical component in the treatment of adult and pediatric brain tumors. In this test-specific episode of the "Answers From the Lab" podcast, Robert Jenkins, M.D., Ph.D., explains how Mayo Clinic Laboratories' chromosomal microarray provides more comprehensive and accurate tumor analysis compared with other test methods.
"The array test covers all the possibilities," Dr. Jenkins says. "It easily finds the various mutations that are essential for diagnosis and prognosis."
He notes that the chromosomal microarray is more accurate than fluorescence in situ hybridization (FISH), and requires less tumor content than methylation assay.
Each microarray is analyzed by an experienced Mayo Clinic pathologist. "We use our specialist knowledge about brain tumors and what we see in the microarray to generate a meaningful report that can guide a care plan for these complex brain tumors," Dr. Jenkins says.
Listen to learn more about Mayo Clinic Laboratories' chromosomal microarray assay.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Specimen Required (submit only 1 of the following specimens):
Ordering Guidance: This test is not performed on fresh tissue specimens. If testing is needed for fresh tissue specimens, order CMAT / Chromosomal Microarray, Tumor, Fresh or Frozen using Affymetrix Cytoscan HD.
Necessary Information: A reason for testing and pathology report are required for testing to be performed. Send information with specimen. Acceptable pathology reports include working drafts, preliminary pathology or surgical pathology reports.
Analytic time: 10 to 21 days
Days performed: Monday through Friday
Patients with elevated LDL or "bad" cholesterol face even greater risk if their levels of small dense LDL cholesterol are also high. Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D., explain how Mayo Clinic Laboratories' sdLDL-c assay measures concentrations of the small dense LDL subtype, to better guide clinical care.
Identifying a precise genetic cause of hearing loss impacts clinical management. Nicole Boczek, Ph.D., and Melanie Meyer, M.S., CGC, explain how Mayo Clinic Laboratories' updated panel yields comprehensive results for optimal patient care.
In this test-specific episode of the "Answers From the Lab" podcast, Wei Shen, Ph.D., explains how Mayo Clinic Laboratories' new breast cancer panel provides rapid results to guide critical decisions about treatment and screening.